| Coelho et al. |
58 |
28.9% MSKCC high risk, 36% PS≥2, 27% ≥ 65 years old, 29 % without nephrectomy |
12% fatigue, 12% hypertension, 7% thrombocytopenia, 5% neutropenia, 5% hand-foot syndrome. |
Assessed in 45 patients: 40% partial response, 35.6% stable disease |
7.6 |
14.1 |
| Motzer et al. (11, 12) |
375 |
10% without nephrectomy, 6% MSKCC high risk, PS 0-1, median age of 62 years |
12% hypertension, 11% fatigue, 9% hand-foot syndrome and 9% diarrhea. |
47% |
11 |
26.4 |
| Gore et al. (16) |
4564 |
11% without nephrectomy, 9% MSKCC high risk, 14% PS≥ 2, 32% age ≥ 65 years |
8% fatigue, 8% thrombocytopenia, 6% neutropenia, 6% asthenia, 6 % HFS, 5 % diarrhea |
1% complete response, 16% partial response, 59% stable disease |
10.9 |
18.4 |
| Ansari et al. (17) |
56 |
14 % without nephrectomy, 18% PS≥2, median age of 61 years, 50% received interferon alpha as previous treatment |
21 % mucositis, 14% leucopenia, 13% neutropenia, 9% thrombocytopenia, 7% increased creatinine, 5% diarrhea, 5% hypertension, 5% HFS |
Assessed in 49 patients: 41% partial response, 37% stable disease |
12.2 no difference between patients receiving and not receiving immunotherapy |
18.2 no difference between patients receiving and not receiving immunotherapy |
| Hong et al. (18) |
76 |
Median age of 57.5 years, 10.5% PS =2, 10% MSKCC high risk, 4.3% without nephrectomy |
38.2% thrombocytopenia, 10.5 % fatigue, 10.5% mucositis, 9.2 % HFS |
27.6% objective response and 84.2% with controlled disease |
7.2 |
22.8 |
